66 related articles for article (PubMed ID: 23228005)
1. No clinical harm from a massive exenatide overdose: a short report.
Krishnan L; Dhatariya K; Gerontitis D
Clin Toxicol (Phila); 2013 Jan; 51(1):61. PubMed ID: 23228005
[No Abstract] [Full Text] [Related]
2. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia.
Cohen V; Teperikidis E; Jellinek SP; Rose J
Clin Toxicol (Phila); 2008 Apr; 46(4):346-7. PubMed ID: 17852164
[No Abstract] [Full Text] [Related]
3. Exenatide and renal failure.
Ferrer-Garcia JC; Martinez-Chanza N; Tolosa-Torréns M; Sánchez-Juan C
Diabet Med; 2010 Jun; 27(6):728-9. PubMed ID: 20546299
[No Abstract] [Full Text] [Related]
4. Exenatide-induced depression in a geriatric patient.
Kohen I; Lester P
Int J Geriatr Psychiatry; 2008 Apr; 23(4):443-4. PubMed ID: 18383195
[No Abstract] [Full Text] [Related]
5. Attempted suicide with liraglutide overdose did not induce hypoglycemia.
Nakanishi R; Hirose T; Tamura Y; Fujitani Y; Watada H
Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376
[TBL] [Abstract][Full Text] [Related]
6. Exenatide and rare adverse events.
Ahmad SR; Swann J
N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
[No Abstract] [Full Text] [Related]
7. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
Tuttle KR; Heilmann C; Hoogwerf BJ; Brown C; Anderson PW
Am J Kidney Dis; 2013 Aug; 62(2):396-8. PubMed ID: 23684754
[No Abstract] [Full Text] [Related]
8. A cohort study of acute pancreatitis in relation to exenatide use.
Dore DD; Bloomgren GL; Wenten M; Hoffman C; Clifford CR; Quinn SG; Braun DK; Noel RA; Seeger JD
Diabetes Obes Metab; 2011 Jun; 13(6):559-66. PubMed ID: 21320263
[TBL] [Abstract][Full Text] [Related]
9. Exenatide: excessive weight loss.
Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
[No Abstract] [Full Text] [Related]
10. Exenatide and acute pancreatitis.
Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
[TBL] [Abstract][Full Text] [Related]
11. Exenatide (Byetta) for type 2 diabetes.
Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
[TBL] [Abstract][Full Text] [Related]
12. A case report of allergy to exenatide.
Pérez E; Martínez-Tadeo J; Callero A; Hernández G; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2014; 2(6):822-3. PubMed ID: 25439386
[No Abstract] [Full Text] [Related]
13. Valproate toxicity in a child: two novel observations.
Ray S; Skellett S
Clin Toxicol (Phila); 2013 Jan; 51(1):60. PubMed ID: 23170820
[No Abstract] [Full Text] [Related]
14. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
15. Exenatide (exendin-4)-induced pancreatitis: a case report.
Denker PS; Dimarco PE
Diabetes Care; 2006 Feb; 29(2):471. PubMed ID: 16443920
[No Abstract] [Full Text] [Related]
16. Acute tubulointerstitial nephritis following treatment with exenatide.
Nandakoban H; Furlong TJ; Flack JR
Diabet Med; 2013 Jan; 30(1):123-5. PubMed ID: 22762797
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
[TBL] [Abstract][Full Text] [Related]
18. Reply to Rees et al. Acute tubulointerstitial nephritis following treatment with exenatide.
Nandakoban H; Flack J; Furlong T
Diabet Med; 2013 Feb; 30(2):252. PubMed ID: 23088538
[No Abstract] [Full Text] [Related]
19. Response to Nandakoban et al. Acute tubulointerstitial nephritis following treatment with exenatide.
Rees DO; Price DE; Bain SC; Stephens JW
Diabet Med; 2013 Feb; 30(2):251-2. PubMed ID: 22998130
[No Abstract] [Full Text] [Related]
20. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
